Edition:
United States

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

6.49USD
3:59pm EST
Change (% chg)

$-0.58 (-8.20%)
Prev Close
$7.07
Open
$7.09
Day's High
$7.19
Day's Low
$6.41
Volume
527,788
Avg. Vol
219,759
52-wk High
$15.81
52-wk Low
$6.41

Chart for

About

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $894.46
Shares Outstanding(Mil.): 47.15
Dividend: --
Yield (%): --

Financials

  AKBA.OQ Industry Sector
P/E (TTM): -- 69.72 34.40
EPS (TTM): -3.62 -- --
ROI: -85.01 9.00 14.96
ROE: -147.39 10.14 16.53

Former Akebia employee gets three years in prison for insider trading

A former Akebia Therapeutics Inc employee was sentenced on Monday to three years in prison after being convicted of working with a friend at a rival drugmaker to engage in insider trading based on information they learned about drug studies, according to the office of Massachusetts U.S. Attorney Andrew Lelling.

Nov 06 2018

Ex-Akebia employee jailed for night as insider trading trial starts

BOSTON A former Akebia Therapeutics Inc employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday.

Jun 26 2018

CORRECTED-Ex-Akebia employee jailed for night as insider trading trial starts

BOSTON, June 26 A former Akebia Therapeutics Inc employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday.

Jun 26 2018

Earnings vs. Estimates